L'intérêt à découvert pour LeMaitre Vascular donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de LeMaitre Vascular. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

LeMaitre Vascular (NASDAQ:LMAT) Stock, Rapport sur les intérêts à découvert

LeMaitre Vascular

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

LeMaitre Vascular Inc

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and maintains $92 price target.

News

Price Target

Analyst Ratings

LMAT

Barrington Research Maintains Outperform on LeMaitre Vascular, Maintains $92 Price Target

Acadia Healthcare Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achc#NASDAQ">ACHC</a>) and Methodist Jennie Edmundson Hospital recently conducted a groundbreaking ceremony for a cutting-edge behavioral health hospital in Council Bluffs, IA. Plans to establish the hospital were announced in July 2023 as part of the joint-venture partnership between ACHC and Omaha-based Methodist Health System. The Methodist Jennie Edmundson Hospital is part of Methodist Health System.&nbsp;
The new facility will be named Methodist Jennie Edmundson Behavioral Health and is likely to commence operations in 2026. It will feature 96 inpatient beds, with 24 specifically designated for addressing the mental health needs of children and adolescents. It will also offer intensive outpatient services. The hospital will invest in cutting-edge technology and resources to enhance access to high-quality behavioral health services for patients dealing with acute mental health and substance use disorders.
This, in turn, is expected to bring about improved health outcomes for residents of western Iowa and eastern Nebraska. Working closely with local organizations, hospitals and first responders of the two regions will enable the joint venture partners to better serve the targeted regions.
<h2>A Time-Opportune Move on ACHC&#39;s Part</h2>
Opening the Methodist Jennie Edmundson Behavioral Health Hospital is likely to be a time-opportune move considering the dire need for acute and intensive outpatient behavioral health services across the Council Bluffs community. According to the American Hospital Directory, there remains a shortage of more than 300 inpatient behavioral health beds in Iowa and Nebraska, which further substantiates the timeliness of the recent move.
<h2>Benefits to Acadia Healthcare</h2>
New facilities resulting from joint ventures offer a means for ACHC to serve a greater number of patients and earn more revenues.&nbsp;
Acadia Healthcare often resorts to buyouts or joint ventures with renowned U.S. health systems to inaugurate new hospitals or expand existing facilities through bed additions. Its healthcare portfolio comprised 258 behavioral healthcare facilities across 38 states and Puerto Rico as of June 30, 2024. Management anticipates adding more than 400 beds to existing facilities in 2024.
<h2>ACHC Stock&#39;s Price Performance</h2>
Shares of Acadia Healthcare have gained 19.2% in the past month compared with the industry&#39;s 8.5% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4d/75809.jpg?v=356746199" />
Image Source: Zacks Investment Research
<h2>Zacks Rank &amp; Key Picks</h2>
ACHC currently carries a Zacks Rank #3 (Hold).&nbsp;
Some better-ranked stocks in the Medical space are LeMaitre Vascular, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmat#NASDAQ">LMAT</a>)&nbsp;, Avanos Medical, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/avns#NYSE">AVNS</a>) and The Ensign Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensg#NASDAQ">ENSG</a>). While LeMaitre Vascular sports a Zacks Rank #1 (Strong Buy), Avanos Medical and Ensign Group carry a Zacks Rank #2 (Buy) at present.
LeMaitre Vascular&#39;s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 8.87%. The Zacks Consensus Estimate for LMAT&#39;s 2024 earnings implies an improvement of 37% while the same for revenues indicates growth of 13% from the respective 2023 figures.
The Zacks Consensus Estimate for LMAT&#39;s&nbsp; earnings has moved 4.5% north in the past 30 days. Shares of LeMaitre Vascular have gained 2.4% in the past month.
Avanos Medical&#39;s earnings surpassed estimates in three of the last four quarters and missed the mark once, the average surprise being 5.69%. The Zacks Consensus Estimate for AVNS&#39; 2024 earnings indicates a 35% rise from the 2023 figure.
The consensus mark for AVNS&#39;&nbsp; earnings has moved 0.7% north in the past 30 days. Shares of Avanos Medical have gained 6.1% in the past month.
Ensign Group&#39;s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 1.40%. The Zacks Consensus Estimate for ENSG&#39;s 2024 earnings indicates an 14.1% rise while the same for revenues implies an improvement of 13.1% from the respective 2023 reported figures.&nbsp;
The consensus mark for ENSG&#39;s earnings has moved up 0.7% in the past 30 days.&nbsp; Shares of Ensign Group have gained 1.8% in the past month.
<a href="https://www.zacks.com/stock/news/2328512/acadia-healthcare-expands-behavioral-health-services-in-iowa?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2328512">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Mid Cap

Health Care

Small Cap

Management

Markets

Trading Ideas

General

ACHC

AVNS

ENSG

Acadia Healthcare Expands Behavioral Health Services in Iowa

On August 26, 2024, LeMaitre Vascular, Inc. (the "Company"), announced that Joseph P. Pellegrino, Jr. will retire as an employee of the company, including as Chief Financial Officer, effective as of March 7, 2025, following the anticipated filing of the 2024 Fiscal Year 10-K. Mr. Pellegrino will remain on the Board of Directors. The Company thanks Mr. Pellegrino for his 19 years of executive service and is thrilled to retain his Board-level services going forward. Mr. Pellegrino was re-elected to the Board in June 2024 and will serve out the remainder of this term until June 2027. The Company will conduct a search for a replacement Chief Financial Officer and anticipates Mr. Pellegrino being involved in the hiring, selection and onboarding process. As of August 26, 2024, the Company reaffirms its August 1, 2024 financial guidance covering Q3 2024 and Full-Year 2024.

Guidance

Lemaitre Vascular Announces Joseph P. Pellegrino, Jr. Will Retire As An Employee Of The Company As Well As CFO, Effective As Of March 7, 2025; Co Reaffirms August 1, 2024 Financial Guidance Covering Q3 2024 And Full-Year 2024

JMP Securities analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Market Outperform and raises the price target from $77 to $100.

JMP Securities Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $100

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and raises the price target from $79 to $92.

Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $92

Business Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Q3 2024 Guidance</td>
<td>Full Year 2024 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Sales</td>
<td>$52.7mm - $54.7mm (Mid: $53.7mm, +13%, +14% Org.)</td>
<td>$216.8mm - $220.8mm (Mid: $218.8mm, +13%, + 13% Org.)</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>68.0%</td>
<td>68.4%</td>
</tr>
<tr>
<td>Op. Income</td>
<td>$11.3mm - $12.7mm (Mid: $12.0mm, +31%) &nbsp;</td>
<td>$49.7mm - $52.5mm (Mid $51.1mm, +39%) (Mid: $51.1mm, +37% Ex-Special)&#x2A;</td>
</tr>
<tr>
<td>Op. Margin (Mid)</td>
<td>22%</td>
<td>23%</td>
</tr>
<tr>
<td>EPS</td>
<td>$0.42 - $0.46 (Mid: $0.44, +32%)</td>
<td>$1.82 - $1.91 (Mid: $1.86, +39%) (Mid: $1.86, +37% Ex-Special)&#x2A;</td>
</tr>
</tbody>
</table>
</figure>
&#x2A;Special charges in 2023 were related to the St. Etienne factory closure.

LeMaitre Vascular Sees Q3 EPS $0.42-$0.46 Vs $0.42 Est.; Revenue $52.7M-$54.7M Vs $52.35M Est.; FY24 EPS $1.82-$1.91 Vs $1.77 Est.; Revenue $216.8M-$220.8M Vs $215.05M Est.

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.47 by 12.77 percent. The company reported quarterly sales of $55.849 million which beat the analyst consensus estimate of $54.986 million by 1.57 percent. This is a 11.44 percent increase over sales of $50.115 million the same period last year.

LeMaitre Vascular Q2 2024 GAAP EPS $0.53 Beats $0.47 Estimate, Sales $55.849M Beat $54.986M Estimate

GE HealthCare Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gehc#NASDAQ">GEHC</a>), along with Heart Hospital of New Mexico at Lovelace Medical Center (HHNM), announced HHNM as the first location in the United States to install GE HealthCare&#39;s latest Allia Image Guided System Pulse. The Allia IGS Pulse system is expected to provide excellent image quality and improve workflow for the diagnosis and treatment of cardiovascular diseases (CVDs).
HHNM expects to use the Allia IGS Pulse system in its cardiac electrophysiology lab to plan, guide and monitor the outcomes of electrophysiological procedures, such as cardiac ablations and cardiac catherizations, among others.
The latest installation is expected to strengthen GE HealthCare&#39;s foothold in the CVD treatment space.
<h3>Significance of the Installation</h3>
According to a report by the American Heart Association, heart disease has been the leading cause of death in the United States for decades. Per the report, nearly half (48.6%) of all people over the age of 20 years have some type of CVD, including coronary heart disease, heart failure, stroke and, most notably, high blood pressure.
Per GE HealthCare&#39;s management, the collaboration with HHNM for the first U.S. installation of the Allia IGS Pulse System will likely address current healthcare challenges and provide optimal experiences for patients and their providers.
HHNM&#39;s management believes that as New Mexico&#39;s only hospital exclusively dedicated to heart care, it will be able to provide innovative treatment options for the patients and keep them close to home for care.
<h3>Industry Prospects</h3>
Per a report by MarketsandMarkets, the global electrophysiology market was valued at $8.2 billion in 2023 and is anticipated to reach $15.1 billion by 2028 at a CAGR of 13%. Factors like the increasing prevalence of CVDs and technological advancements are likely to drive the market.
Given the market potential, the latest installation is expected to provide a significant boost to GE HealthCare&#39;s business.
<h3>Recent Developments</h3>
This month, GE HealthCare, along with MediView XR Inc., announced the successful first installation and clinical cases using the OmnifyXR Interventional Suite at North Star Vascular and Interventional in Minneapolis, MN.
The same month, GE HealthCare inked an agreement with Salud Digna. The agreement aims to deploy digital solutions to improve the efficiency of care protocols for clinicians on Computed tomography, Magnetic resonance and ultrasound systems across Mexico.
Last month, GE HealthCare collaborated with Medis Medical Imaging. The collaboration is aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease. Both companies are expected to focus on the integration of Medis Quantitative Flow Ratio into GE HealthCare&#39;s cath lab environment built around the Allia Platform to enable a seamless user experience.
<h3>Price Performance</h3>
Shares of GE HealthCare have gained 1.6% in the past year against the industry&#39;s 26.4% decline. The S&amp;P 500 has witnessed 26.1% growth in the said time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/96/69509.jpg?v=1932984697" /> 
Image Source: Zacks Investment Research
<h3>Zacks Rank &amp; Key Picks</h3>
Currently, GE HealthCare carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), LeMaitre Vascular, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmat#NASDAQ">LMAT</a>) and Ecolab Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>).
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%.
DaVita&#39;s shares have gained 47.9% compared with the industry&#39;s 16.4% rise in the past year.
LeMaitre Vascular, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 18.5%. LMAT&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average being 10.1%.
LeMaitre Vascular has gained 19.8% against the industry&#39;s 1.8% decline in the past year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.3%. ECL&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.3%.
Ecolab&#39;s shares have rallied 34.6% against the industry&#39;s 10.8% decline in the past year.
<a href="https://www.zacks.com/stock/news/2293112/ge-healthcare-s-gehc-new-tie-up-to-boost-cvd-workflow?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2293112">To read this article on Zacks.com click here.</a>

GEHC

GE HealthCare's New Tie-Up to Boost CVD Workflow

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $82.75, along with a high estimate of $100.00 and a low estimate of $75.00. This current average reflects an increase of 24.12% from the previous average price target of $66.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1717164022_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive LeMaitre Vascular is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Wittes</td>
<td>Roth MKM</td>
<td>Announces</td>
<td>Buy</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$79.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$77.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$59.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to LeMaitre Vascular. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of LeMaitre Vascular compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for LeMaitre Vascular's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into LeMaitre Vascular's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LMAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on LeMaitre Vascular analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know LeMaitre Vascular Better</h2>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>Financial Milestones: LeMaitre Vascular's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: LeMaitre Vascular's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 13.6%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: LeMaitre Vascular's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.49% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): LeMaitre Vascular's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.26% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): LeMaitre Vascular's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.82%, the company showcases efficient use of assets and strong financial health.
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 4 Analyst Ratings For LeMaitre Vascular

Roth MKM analyst Jason Wittes reinstates LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Buy and announces $100 price target.

Initiation

Roth MKM Reinstates Buy on LeMaitre Vascular, Announces $100 Price Target

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and raises the price target from $69 to $79.

Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $79

JMP Securities analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Market Outperform and raises the price target from $72 to $77.

JMP Securities Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $77

WIIM

LeMaitre Vascular shares are trading higher after the company reported strong Q1 earnings and issued EPS guidance above estimates.

LeMaitre Vascular Sees Q2 EPS $0.45-$0.50 vs $0.44 Est., Sales $53.7M-$56.1M vs $54.29M Est.; Sees FY24 EPS $1.73-$1.84 vs $1.65 Est., Sales $212.7M-$217.3M vs $211.7M Est.

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.38 by 15.79 percent. This is a 62.96 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $53.478 million which beat the analyst consensus estimate of $51.506 million by 3.83 percent. This is a 13.60 percent increase over sales of $47.075 million the same period last year.

LeMaitre Vascular Q1 2024 GAAP EPS $0.44 Beats $0.38 Estimate, Sales $53.478M Beat $51.506M Estimate

Stifel analyst Rick Wise upgrades LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) from Hold to Buy and raises the price target from $59 to $75.

Upgrades

Stifel Upgrades LeMaitre Vascular to Buy, Raises Price Target to $75

A large exercise of company stock options by George LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) was disclosed in a new SEC filing on March 26, as part of an insider exercise.
What Happened: LeMaitre, Chairman and CEO at LeMaitre Vascular, exercised stock options for 14,808 shares of LMAT stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774924009454//Archives/edgar/data/1158895/000143774924009454/0001437749-24-009454-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The exercise price of the options was $47.93 per share.
The latest update on Wednesday morning shows LeMaitre Vascular shares down by 0.0%, trading at $65.9. At this price, LeMaitre's 14,808 shares are worth $266,154.
<h3>All You Need to Know About LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>Key Indicators: LeMaitre Vascular's Financial Health</h3>
Revenue Growth: LeMaitre Vascular's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 19.36%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 68.05%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): LeMaitre Vascular's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.38.
</li>
</ul>
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: LeMaitre Vascular's current Price to Earnings (P/E) ratio of 49.09 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 7.62, LeMaitre Vascular's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 28.24, LeMaitre Vascular demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>The Insider's Guide to Important Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Engaging In Options Activity, George LeMaitre Exercises Options Valued At $266K In LeMaitre Vascular

It was reported on March 5, that George LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) executed a significant insider sell, according to an SEC filing.
What Happened: LeMaitre's recent move involves selling 101,478 shares of LeMaitre Vascular. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774924006521//Archives/edgar/data/1158895/000143774924006521/0001437749-24-006521-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value is $6,944,096.
In the Tuesday's morning session, LeMaitre Vascular's shares are currently trading at $67.92, experiencing a down of 0.0%.
<h3>Unveiling the Story Behind LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>A Deep Dive into LeMaitre Vascular's Financials</h3>
Revenue Growth: Over the 3 months period, LeMaitre Vascular showcased positive performance, achieving a revenue growth rate of 3.1% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 68.05%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): LeMaitre Vascular's EPS is below the industry average. The company faced challenges with a current EPS of 0.38. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: LeMaitre Vascular's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 50.7.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 7.87 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): LeMaitre Vascular's EV/EBITDA ratio of 29.12 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Transaction: George LeMaitre Sells $6.94M Worth Of LeMaitre Vascular Shares

On March 5, it was revealed in an SEC filing that Joseph Pellegrino JR, Chief Financial Officer at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) executed a significant exercise of company stock options.
What Happened: A notable Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774924006519//Archives/edgar/data/1158895/000143774924006519/0001437749-24-006519-index.htm">U.S. Securities and Exchange Commission</a> revealed that JR, Chief Financial Officer at LeMaitre Vascular, exercised stock options for 33,884 shares of LMAT, resulting in a transaction value of $1,075,673.
LeMaitre Vascular shares are trading, exhibiting down of 0.0% and priced at $67.92 during Tuesday's morning. This values JR's 33,884 shares at $1,075,673.
<h3>Delving into LeMaitre Vascular's Background</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>Understanding the Numbers: LeMaitre Vascular's Finances</h3>
Revenue Growth: LeMaitre Vascular displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 3.1%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 68.05%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, LeMaitre Vascular exhibits below-average bottom-line performance with a current EPS of 0.38.
</li>
</ul>
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: LeMaitre Vascular's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 50.7.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 7.87, LeMaitre Vascular's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 29.12 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes To Focus On</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Strategic Sale: Joseph Pellegrino JR Decides To Exercise Options Worth $1.08M At LeMaitre Vascular

Barrington Research has decided to maintain its Outperform rating of LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) and raise its price target from $66.00 to $69.00.
Shares of LeMaitre Vascular are trading up 3.28% over the last 24 hours, at $64.15 per share.
A move to $69.00 would account for a 7.56% increase from the current share price.
<h3>About LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Barrington Research Maintains Outperform Rating for LeMaitre Vascular: Here's What You Need To Know

Lake Street analyst Frank Takkinen assigned a Buy rating on Lemaitre Vascular (LMAT – Research Report) today and set a price target of $105.00. Fra...

Lemaitre Vascular: A Strong Buy on Sustained Growth and Strategic Acquisitions

Analyst Michael Petusky of Barrington maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report), boosting the price target to $92.00. M...

Buy Rating Affirmed for Lemaitre Vascular Amid Strong Fiscal Performance and Growth Prospects

Dividend Champion, Contender, And Challenger Highlights: Week Of August 11

Holding Or Selling? - July Dividend Income Report

In a report released today, Daniel Stauder from JMP Securities reiterated a Buy rating on Lemaitre Vascular (LMAT – Research Report), with a price ...

Lemaitre Vascular's Strong Financial Performance and Growth Potential Warrant a Buy Rating

Dividend Champion, Contender, And Challenger Highlights: Week Of August 25

Lemaitre Vascular (LMAT) has issued an announcement. LeMaitre Vascular, Inc. has announced the retirement of its Chief Financial Officer, Joseph P....

LeMaitre Vascular CFO Retires, Joins Board of Directors

Lake Street analyst Frank Takkinen reiterated a Buy rating on Lemaitre Vascular (LMAT – Research Report) today and set a price target of $105.00. T...

Lemaitre Vascular (LMAT) Gets a Buy from Lake Street

Conestoga Capital Advisors Q2 2024 Commentary

Analyst Michael Petusky from Barrington maintained a Buy rating on Lemaitre Vascular (LMAT – Research Report) and keeping the price target at $92.0...

Comments

LeMaitre Vascular

Intérêt court

LeMaitre Vascular (NASDAQ:LMAT) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL